Does Wegovy or Ozempic Help Sleep Apnea?

If you have obstructive sleep apnea (OSA) and you are on — or considering — Wegovy or Ozempic, the honest answer to "does it help my sleep apnea?" hinges on one distinction that the marketing tends to blur. Tirzepatide, sold as Zepbound, is FDA-approved to treat obstructive sleep apnea. Semaglutide — sold as Wegovy and Ozempic — is not. That is not a technicality. It is the difference between a drug with a dedicated, positive Phase 3 sleep-apnea trial behind it and a drug whose only plausible OSA benefit is the indirect one that comes from losing weight. Both can be true at once: semaglutide may well help some people's sleep apnea by helping them lose weight, but that is an off-label, weight-loss-mediated effect with far thinner direct trial data — not an approved treatment for the condition.

This guide separates what is proven from what is merely plausible, because OSA is a serious condition and "my weight-loss drug probably helps" is not the same as "this is a treatment for my sleep apnea."

The headline: only tirzepatide is FDA-approved for OSA

In December 2024, the FDA approved Zepbound (tirzepatide) for moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved specifically to treat OSA. That approval rests on SURMOUNT-OSA, a pair of Phase 3, randomized, placebo-controlled trials published in the New England Journal of Medicine¹. Wegovy and Ozempic (semaglutide) carry no such indication. Their FDA labels cover chronic weight management (Wegovy) and type 2 diabetes (Ozempic) — not sleep apnea³. So if a provider or ad implies semaglutide is "for" sleep apnea, that is off-label framing; the only GLP-1-class drug the FDA has cleared for OSA is tirzepatide².

What SURMOUNT-OSA actually showed (and why it's tirzepatide's win, not semaglutide's)

SURMOUNT-OSA enrolled adults with moderate-to-severe OSA and obesity, split into two trials — one for people not using a CPAP/positive-airway-pressure machine, one for people who were. Over 52 weeks, tirzepatide produced large reductions in the apnea-hypopnea index (AHI) — the number of times breathing stops or shallows per hour of sleep, and the core measure of OSA severity. In the trial of people not on PAP, mean AHI fell by about 25.3 events per hour with tirzepatide versus about 5.3 with placebo (a treatment difference of roughly 20 events/hour); in the PAP trial, it fell by about 29.3 events per hour versus about 5.5 with placebo (a difference of roughly 24 events/hour)¹. Those are clinically meaningful drops — enough to move many participants down a severity category — alongside weight loss, lower hypoxic burden, lower blood pressure, and reduced inflammation¹.

That is the evidence base that earned the approval. There is no equivalent dedicated, FDA-registrational sleep-apnea trial for semaglutide. So semaglutide does not get to borrow tirzepatide's result — they are different molecules, and the OSA approval belongs to tirzepatide alone. (For why these two drugs are not interchangeable and why doses never convert one-to-one, see our semaglutide vs tirzepatide breakdown and our guide to switching from Zepbound to Wegovy.)

Why semaglutide *might* still help — the weight-loss mechanism

Here is the part that is genuinely reassuring, stated honestly. Obstructive sleep apnea is strongly driven by excess weight — fat around the neck and upper airway narrows it, and abdominal fat reduces lung volumes — so losing weight is a long-established way to reduce OSA severity, independent of any specific drug. A randomized lifestyle and weight-loss trial, INTERAPNEA, showed that an intensive weight-loss intervention significantly reduced OSA severity and even pushed some participants into remission⁹. Weight loss is a recognized first-line lever for OSA in people with obesity.

Semaglutide produces substantial weight loss — about 15% of body weight on average in its pivotal STEP 1 trial⁵. So the logical inference is that semaglutide should reduce OSA severity to the extent that it reduces weight — a weight-loss-mediated benefit. That inference is supported by the broader GLP-1 class, not just tirzepatide: an older randomized trial, SCALE Sleep Apnea, found that the GLP-1 drug liraglutide reduced AHI in people with obesity and moderate-to-severe OSA, and the reduction tracked with weight loss⁷. And a systematic review and meta-analysis of GLP-1-receptor-agonist-based therapies in OSA found the class significantly lowered AHI overall — while noting the effect was driven mostly by tirzepatide, with the larger reductions concentrated there⁸.

So the honest summary is: the class lowers AHI, mostly via weight loss, and semaglutide almost certainly participates in that effect. But "almost certainly, by analogy, via weight loss" is a weaker claim than "proven in a dedicated trial and FDA-approved," which is what tirzepatide has.

Tirzepatide vs semaglutide for OSA: the head-to-head context

Even setting OSA aside, tirzepatide tends to produce more weight loss than semaglutide. In SURMOUNT-5, the direct head-to-head randomized trial, tirzepatide produced about 20.2% body-weight loss versus about 13.7% for semaglutide over 72 weeks¹⁰; tirzepatide's own pivotal obesity trial, SURMOUNT-1, reached up to roughly 21%⁶. Since OSA improvement on these drugs is largely weight-mediated, the drug that drives more weight loss would be expected to drive more AHI reduction — which is exactly the pattern the GLP-1-OSA meta-analysis observed⁸. That is a second reason tirzepatide, not semaglutide, is the one carrying the OSA indication.

None of this means semaglutide is useless for someone with both obesity and OSA. If weight is the right target for a given patient, the weight loss semaglutide delivers is real and may improve sleep apnea as a downstream benefit. It simply is not an approved OSA treatment, and it should not be presented as one.

What this means for you — and what it doesn't

A few honest takeaways if you have OSA:

• •Semaglutide is not a sleep-apnea drug. Wegovy/Ozempic are approved for weight management and diabetes, respectively — not OSA³. Any OSA benefit is off-label and weight-loss-mediated.
• •Tirzepatide (Zepbound) is the approved option if a drug specifically for OSA is the goal, based on SURMOUNT-OSA¹².
• •Neither replaces CPAP on its own decision. OSA is a serious condition tied to cardiovascular risk; SURMOUNT-OSA even studied tirzepatide in people on PAP. Do not stop CPAP or any prescribed OSA therapy because you started a weight-loss drug — that is a conversation for your sleep physician, guided by a repeat sleep study, not a self-made call.
• •Weight loss genuinely helps OSA regardless of how you achieve it⁹ — so the weight you lose on semaglutide is not "wasted" for your sleep apnea; it just is not the same as a registered treatment.

Both semaglutide and tirzepatide are prescription-only drugs with a boxed warning and a real side-effect profile, and any OSA management decision belongs with your clinician and sleep specialist. For the full picture of what semaglutide does and doesn't do, start with our pillar, Semaglutide: how it works, results and side effects. If you want to compare providers and pricing for semaglutide, see our best semaglutide providers roundup; and for the broader heart and metabolic benefits that are well-established for semaglutide, see do Wegovy and Ozempic protect the heart?.